{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [["biological medicine", "bioregulation", "chronic inflammation", "complementary medicine", "ozone therapy", "redox balance"]], "CitationSubset": ["IM"], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "34360655", "DateCompleted": {"Year": "2021", "Month": "08", "Day": "16"}, "DateRevised": {"Year": "2021", "Month": "08", "Day": "16"}, "Article": {"Language": ["eng"], "ArticleDate": [{"Year": "2021", "Month": "07", "Day": "23"}], "ELocationID": ["7890", "10.3390/ijms22157890"], "Journal": {"ISSN": "1422-0067", "JournalIssue": {"Volume": "22", "Issue": "15", "PubDate": {"Year": "2021", "Month": "Jul", "Day": "23"}}, "Title": "International journal of molecular sciences", "ISOAbbreviation": "Int J Mol Sci"}, "ArticleTitle": "Ozone in Medicine. The Low-Dose Ozone Concept and Its Basic Biochemical Mechanisms of Action in Chronic Inflammatory Diseases.", "Abstract": {"AbstractText": ["Low-dose ozone acts as a bioregulator in chronic inflammatory diseases, biochemically characterized by high oxidative stress and a blocked regulation. During systemic applications, \"Ozone peroxides\" are able to replace H<sub>2</sub>O<sub>2</sub> in its specific function of regulation, restore redox signaling, and improve the antioxidant capacity. Two different mechanisms have to be understood. Firstly, there is the direct mechanism, used in topical treatments, mostly via radical reactions. In systemic treatments, the indirect, ionic mechanism is to be discussed: \"ozone peroxide\" will be directly reduced by the glutathione system, informing the nuclear factors to start the regulation. The GSH/GSSG balance outlines the ozone dose and concentration limiting factor. Antioxidants are regulated, and in the case of inflammatory diseases up-regulated; cytokines are modulated, here downregulated. Rheumatoid arthritis RA as a model for chronic inflammation: RA, in preclinical and clinical trials, reflects the pharmacology of ozone in a typical manner: SOD (superoxide dismutase), CAT (catalase) and finally GSH (reduced glutathione) increase, followed by a significant reduction of oxidative stress. Inflammatory cytokines are downregulated. Accordingly, the clinical status improves. The pharmacological background investigated in a remarkable number of cell experiments, preclinical and clinical trials is well documented and published in internationally peer reviewed journals. This should encourage clinicians to set up clinical trials with chronic inflammatory diseases integrating medical ozone as a complement."]}, "AuthorList": [{"Identifier": ["0000-0003-0328-016X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medical Society for the Use of Ozone in Prevention and Therapy, Iffezheim, D-76473 Baden-Baden, Germany."}], "LastName": "Viebahn-Haensler", "ForeName": "Renate", "Initials": "R"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacy and Food Institute, University of Havana, Coronela, Lisa, Havana 10 400, Cuba."}], "LastName": "Le\u00f3n Fern\u00e1ndez", "ForeName": "Olga Sonia", "Initials": "OS"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Int J Mol Sci", "NlmUniqueID": "101092791", "ISSNLinking": "1422-0067"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antioxidants"}, {"RegistryNumber": "0", "NameOfSubstance": "Cytokines"}, {"RegistryNumber": "0", "NameOfSubstance": "Oxidants, Photochemical"}, {"RegistryNumber": "66H7ZZK23N", "NameOfSubstance": "Ozone"}, {"RegistryNumber": "EC 1.11.1.6", "NameOfSubstance": "Catalase"}, {"RegistryNumber": "GAN16C9B8O", "NameOfSubstance": "Glutathione"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["administration & dosage"], "DescriptorName": "Antioxidants"}, {"QualifierName": ["drug therapy", "etiology", "pathology"], "DescriptorName": "Arthritis, Experimental"}, {"QualifierName": ["drug therapy", "etiology", "pathology"], "DescriptorName": "Arthritis, Rheumatoid"}, {"QualifierName": ["metabolism"], "DescriptorName": "Catalase"}, {"QualifierName": ["metabolism"], "DescriptorName": "Cytokines"}, {"QualifierName": ["metabolism"], "DescriptorName": "Glutathione"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["drug therapy", "etiology", "pathology"], "DescriptorName": "Inflammation"}, {"QualifierName": ["administration & dosage"], "DescriptorName": "Oxidants, Photochemical"}, {"QualifierName": [], "DescriptorName": "Oxidation-Reduction"}, {"QualifierName": [], "DescriptorName": "Oxidative Stress"}, {"QualifierName": ["administration & dosage"], "DescriptorName": "Ozone"}, {"QualifierName": [], "DescriptorName": "Rats"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Sies H. Hydrogen peroxide as a central redox signaling molecule in physiological oxidative stress: Oxidative eustress. Redox Biol. 2017;11:613\u2013619. doi: 10.1016/j.redox.2016.12.035.", "ArticleIdList": ["10.1016/j.redox.2016.12.035", "PMC5256672", "28110218"]}, {"Citation": "Marinho H.S., Real C., Cyrne L., Soares H., Antunes F. Hydrogen peroxide sensing, signaling and regulation of transcription factors. Redox Biol. 2014;2:535\u2013562. doi: 10.1016/j.redox.2014.02.006.", "ArticleIdList": ["10.1016/j.redox.2014.02.006", "PMC3953959", "24634836"]}, {"Citation": "Wash\u00fcttl J., Viebahn R. Biochemische Aspekte der Ozon-Sauerstoff Theapie. Ars Med. 1986;5:194\u2013199. (In German)"}, {"Citation": "Lell B., Viebahn R., Kremsner P. The activity of ozone against plasmodium falciparum. Ozone Sci. Eng. 2001;23:89\u201393. doi: 10.1080/01919510108961991.", "ArticleIdList": ["10.1080/01919510108961991"]}, {"Citation": "Hoffmann A., Viebahn R. \u00dcber den Einfluss von Ozon auf die 2,3 Diphosphoglyzerat-Synthese in Erythrozyten-Konzentraten. In: Viebahn-H\u00e4nsler R., Knoch H.G., editors. Ozon-Handbuch, Grundlagen-Pr\u00e4vention-Therapie. Ecomed Publisher; Landsberg, Germany: 2002."}, {"Citation": "Bocci V., Paulesu L. Studies on the biological effects of ozone. 1. Induction of interferon in human leucocytes. Haematologica. 1990;75:510\u2013515.", "ArticleIdList": ["2129118"]}, {"Citation": "Bocci V., Luzzi E., Corradeschi F., Paulesu L., Rossi R., Cardaioli E., Di Simplicio P. Studies on the biological effects of ozone: 4. Cytokine production and glutathione levels in human erythrocytes. Biol. Reg. Hom. Agents. 1993;7:133\u2013138.", "ArticleIdList": ["8023701"]}, {"Citation": "L\u00e9on O.S., Menend\u00e9z S., Merino N., Castillo R., Sam S., P\u00e9rez L., Cruz E., Bocci V. Ozone oxidative preconditioning: A protection against cellular damage by free radicals. Mediat. Inflamm. 1998;7:289\u2013294. doi: 10.1080/09629359890983.", "ArticleIdList": ["10.1080/09629359890983", "PMC1781855", "9792340"]}, {"Citation": "Viebahn-Haensler R., Le\u00f3n Fern\u00e1ndez O.S., Fahmy Z. Ozone in medicine: The low-dose ozone concept. Guidelines and treatment strategies. Ozone Sci. Eng. 2012;34:408\u2013424. doi: 10.1080/01919512.2012.717847.", "ArticleIdList": ["10.1080/01919512.2012.717847"]}, {"Citation": "Hoign\u00e9 J., Bader H. Rate constants of reactions of ozone with organic and inorganic compounds in water I/II. Water Res. 1983;17:173\u2013194. doi: 10.1016/0043-1354(83)90098-2.", "ArticleIdList": ["10.1016/0043-1354(83)90098-2"]}, {"Citation": "Criegee R. Die Ozonolyse. Liebigs Ann. Chem. 1953;538:9. doi: 10.1002/ciuz.19730070303.", "ArticleIdList": ["10.1002/ciuz.19730070303"]}, {"Citation": "Criegee R. Mechanism of Ozone. Angew. Chem. Int. Ed. 1975;14:745\u2013752. doi: 10.1002/anie.197507451.", "ArticleIdList": ["10.1002/anie.197507451"]}, {"Citation": "Werkmeister H. In: Dekubitalgeschw\u00fcre und Die Behandlung Mit der Ozon-Unterdruck-Begasung (German) in Ozon- Handbuch, Grundlagen-Pr\u00e4vention-Therapie. Viebahn-H\u00e4nsler R., Knoch H.G., editors. Ecomed Publisher; Landsberg, Germany: 1995."}, {"Citation": "Haddad E.B., Salmon M., Koto H., Barnes P.J., Adcock I., Chung K.F. Ozone induction of cytokin-induced neutrophil chemotractant and nuclear factor-kB in Rat Lung: Inhibition by Corticosteroids. FEBS Lett. 1996;379:265\u2013268. doi: 10.1016/0014-5793(95)01524-8.", "ArticleIdList": ["10.1016/0014-5793(95)01524-8", "8603703"]}, {"Citation": "Sagai M., Bocci V. Mechanisms of action involved in ozone therapy: Is healing induced via a mild oxidative stress? Med. Gas Res. 2011;1:29. doi: 10.1186/2045-9912-1-29.", "ArticleIdList": ["10.1186/2045-9912-1-29", "PMC3298518", "22185664"]}, {"Citation": "Bocci V., Zanardi I., Travagli V. Oxygen/Ozone as a Medical gas mixture. A Critical evaluation. Med. Gas Res. 2011;1:6. doi: 10.1186/2045-9912-1-6.", "ArticleIdList": ["10.1186/2045-9912-1-6", "PMC3231820", "22146387"]}, {"Citation": "Re L., Martinez-Sanchez G., Bordicchia M., Malcangi G., Pocognoli A., Morales-Segura M.A., Rothchild J.A., Rojas A. Is ozone pre-conditioning effect linked to Nrf2/EpRE activation pathway in vivo? A preliminary result. Eur. J. Pharmacol. 2014;742:158\u2013162. doi: 10.1016/j.ejphar.2014.08.029.", "ArticleIdList": ["10.1016/j.ejphar.2014.08.029", "25218903"]}, {"Citation": "Delgado-Roche L., Riera-Romo M., Mesta F., Hern\u00e1ndez-Matos Y., Barrios J.M., Mart\u00ednez-S\u00e1nchez G., Al-Dalaien S.M. Medical ozone promotes Nrf2 phosphorylation reducing oxidative stress and pro-inflammatory cytokines in multiple sclerosis patients. Eur. J. Pharmacol. 2017;811:148\u2013154. doi: 10.1016/j.ejphar.2017.06.017.", "ArticleIdList": ["10.1016/j.ejphar.2017.06.017", "28623000"]}, {"Citation": "Togi S., Togi M., Nagashima S., Kitay Y., Muromoto R., Kashiwakura J., Miura T., Matsuda T. Implication of NF-kB Activation on Ozone-Induced HO-1 Activation. BPB Rep. 2021;4:59\u201363. doi: 10.1248/bpbreports.4.2_59.", "ArticleIdList": ["10.1248/bpbreports.4.2_59"]}, {"Citation": "Kansanen E., Kuosmanen S.M., Leinonen H., Levonen A.L. The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer. Redox Biol. 2013;1:45\u201349. doi: 10.1016/j.redox.2012.10.001.", "ArticleIdList": ["10.1016/j.redox.2012.10.001", "PMC3757665", "24024136"]}, {"Citation": "Costanzo M., Romeo A., Cisterna B., Calderan L., Bernardi P., Covi V., Tabaracci G., Malatesta M. Ozone at low concentrations does not affect motility and proliferation of cancer cells in vitro. Eur. J. Histochem. 2020;64:3119. doi: 10.4081/ejh.2020.3119.", "ArticleIdList": ["10.4081/ejh.2020.3119", "PMC7137928", "32241095"]}, {"Citation": "Scassellati C., Costanzo M., Cisterna B., Nodari A., Gali\u00e8 M., Cattaneo A., Covi V., Tabaracci G., Bonvicini C., Malatesta M. Effects of mild ozonisation on gene expression and nuclear domains organization in vitro. Toxicol Vitr. 2017;44:100\u2013110. doi: 10.1016/j.tiv.2017.06.021.", "ArticleIdList": ["10.1016/j.tiv.2017.06.021", "28652203"]}, {"Citation": "Viebahn-Haensler R., Le\u00f3n F.O.S., Fahmy Z. Ozone in medicine: Clinical evaluation and evidence classification of the systemic ozone applications, major autohemotherapy and rectal insufflation, according to the requirements for evidence-based medicine. Ozone Sci. Eng. 2016;38:322\u2013345. doi: 10.1080/01919512.2016.1191992.", "ArticleIdList": ["10.1080/01919512.2016.1191992"]}, {"Citation": "Wolff H. Textbook Das Medizinische Ozon (German) Verlag f\u00fcr Medizin; Heidelberg, Germany: 1979."}, {"Citation": "Dranguet V.J., Fraga A., Diaz M.T., Mallok A., Viebahn-H\u00e4nsler R., Fahmy Z., Barbera A., Delgado L., Menendez S., Leon F.O.S. Ozone oxidative postconditioning ameliorates joint damage and decreases proinflammatory cytokine levels and oxidative stress in PG/PS-induced arthritis in rats. Eur. J. Pharmacol. 2013;714:318\u2013324. doi: 10.1016/j.ejphar.2013.07.03.", "ArticleIdList": ["10.1016/j.ejphar.2013.07.03", "23911887"]}, {"Citation": "Le\u00f3n F.O.S., Viebahn-Haensler R., L\u00f3pez C.G., Serrano E.I., Hern\u00e1ndez M.Y., Delgado R.L., Tamargo S.B., Takon O.G., Polo V.J.C. Medical ozone increases methotrexate clinical response and improves cellular redox balance in patients with rheumatoid arthritis. Eur. J. Pharmacol. 2016;789:313\u2013318. doi: 10.1016/j.ejphar.2016.07.031.", "ArticleIdList": ["10.1016/j.ejphar.2016.07.031", "27450487"]}, {"Citation": "Takon O.G., Viebahn-Haensler R., L\u00f3pez C.G., Serrano E.I., Tamargo S.B., Polo V.J.C., S\u00e1nchez S.S., Le\u00f3n F.O.S. Medical Ozone Reduces the Risk of GGT and Alkaline Phosphatase Abnormalities and Oxidative Stress in Rheumatoid Arthritis Patients treated with Methotrexate. SMJ. Arthritis Res. 2017;1:1004."}, {"Citation": "Takon Oru G., Viebahn-Haensler R., Garc\u00eda Fern\u00e1ndez E., Alvarez Almi\u00f1aque D., Polo Vega J.C., Tamargo Santos B., L\u00f3pez Cabreja G., Serrano Espinosa I., Tabares N\u00e1poles N., Le\u00f3n Fern\u00e1ndez O.S. Medical Ozone Effects and Innate Immune Memory in Rheumatoid Arthritis Patients Treated with Methotrexate+Ozone After a Second Cycle of Ozone Exposure. Chronic Pain Manag. 2019;2:114. doi: 10.29011/2576-957X/100014.", "ArticleIdList": ["10.29011/2576-957X/100014"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "6", "Day": "21"}, {"Year": "2021", "Month": "7", "Day": "15"}, {"Year": "2021", "Month": "7", "Day": "18"}, {"Year": "2021", "Month": "8", "Day": "7", "Hour": "1", "Minute": "7"}, {"Year": "2021", "Month": "8", "Day": "8", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "8", "Day": "17", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "7", "Day": "23"}], "PublicationStatus": "epublish", "ArticleIdList": ["34360655", "PMC8346137", "10.3390/ijms22157890", "ijms22157890"]}}], "PubmedBookArticle": []}